Engine Biosciences raises $43M for combo genetic platform
Engine Biosciences has raised $43 million to advance its drug discovery and development platform, which uses next-generation combinatorial genetics to decipher genetic codes. The company will use the funds to expand its portfolio of precision oncology therapeutics, prepare for its first clinical programs, and scale its proprietary technology platform. Read More
MilliporeSigma scales up lipid production for COVID-19 vaccines
MilliporeSigma announced that it has launched a new high-purity synthetic cholesterol product to meet demand for lipids, a component of messenger RNA-based vaccines and therapeutics such as those used for COVID-19. Read More
GNS to develop computer model for prostate cancer
GNS Healthcare has announced plans to develop and launch an in silico digital patient called Gemini to help determine responses to treatment for developers of prostate cancer drugs. Read More
Cellaria launches cell lines for lung cancer therapies
Citing a successful cohort study of patients, Cellaria has launched five new lung cancer cell models to support the development of more effective and targeted drug therapies. Read More
Trial to test oral bacteria protein against cancer
The U.S. Food and Drug Administration has given a Rutgers School of Dental Medicine researcher the green light to treat cancer patients with a new kind of therapy based on a protein produced by an oral bacterium. Read More
Waters launches SARS-CoV-2 LC-MS research kit
Lab equipment supplier Waters has debuted a new SARS-CoV-2 liquid chromatography–mass spectrometry (LC–MS) Kit for research use only. The kit uses an orthogonal analytical method to directly detect and quantify SARS-CoV-2 nucleocapsid peptides. Read More
Twist launches enzymatic fragmentation library prep kit
Twist Bioscience has unveiled its Twist Library Preparation Enzymatic Fragmentation Kit 2.0, an all-in-one solution designed to maximize accuracy and efficiency in library construction and amplification when conducting next-generation sequencing. Read More
Myriad Genetics sells Myriad RBM to Q2 Solutions
Myriad Genetics is selling its Myriad RBM contract research services business to Q2 Solutions, a wholly owned subsidiary of Iqvia, for an undisclosed amount. Read More
Moderna vaccine 100% effective for teens
Moderna announced its phase II/III study of its COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint with no cases of COVID-19 observed in more than 3,700 participants ages 12 to 17 who received two doses of the vaccine. Read More
Ajinomoto expands fill-finish capacity
Ajinomoto Bio-Pharma Services is opening a high-speed, multipurpose fill-finish line in its commercial manufacturing facility located in San Diego, CA. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
